%0 Journal Article %1 Ebert2022-rj %A Ebert, Matthias P %A Meindl-Beinker, Nadja M %A Gutting, Tobias %A Maenz, Martin %A Betge, Johannes %A Schulte, Nadine %A Zhan, Tianzuo %A Weidner, Philip %A Burgermeister, Elke %A Hofheinz, Ralf %A Vogel, Arndt %A Angermeier, Stefan %A Bolling, Claus %A de Wit, Maike %A Jakobs, Ralf %A Karthaus, Meinolf %A Stocker, Gertraud %A Thuss-Patience, Peter %A Leidig, Tobias %A Gaiser, Timo %A Kather, Jakob N %A Haertel, Nicolai %D 2022 %I Elsevier BV %J Lancet Healthy Longev. %K %N 6 %P e417--e427 %T Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial %V 3 %X BACKGROUND: The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 antibodies showed improved progression-free survival and overall survival. We assessed the safety and efficacy of combined nivolumab and ipilimumab therapy in this population. METHODS: This multicentre, open-label, phase 2 trial done in 32 sites in Germany included patients aged 65 years and older with oesophageal squamous cell carcinoma and disease progression or recurrence following first-line therapy. Patients were treated with nivolumab (240 mg fixed dose once every 2 weeks, intravenously) in the safety run-in phase and continued with nivolumab and ipilimumab (nivolumab 240 mg fixed dose once every 2 weeks and ipilimumab 1 mg/kg once every 6 weeks, intravenously). The primary endpoint was overall survival, which was compared with a historical cohort receiving standard chemotherapy in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03416244. FINDINGS: Between March 2, 2018, and Aug 20, 2020, we screened 75 patients with advanced oesophageal squamous cell carcinoma. We enrolled 66 patients (50 76\% men and 16 24\% women; median age 70·5 years IQR 67·0-76·0), 44 (67\%) of whom received combined nivolumab and ipilimumab therapy and 22 (33\%) received nivolumab alone. Median overall survival time at the prespecified data cutoff was 7·2 months (95\% CI 5·7-12·4) and significantly higher than in a historical cohort receiving standard chemotherapy (p=0·0063). The most common treatment-related adverse events were fatigue (12 29\% of 42), nausea (11 26\%), and diarrhoea (ten 24\%). Grade 3-5 treatment-related adverse events occurred in 13 (20\%) of 66 patients. Treatment-related death occurred in one patient with bronchiolitis obliterans while on nivolumab and ipilimumab treatment. INTERPRETATION: Patients aged at least 65 years, with advanced oesophageal squamous cell carcinoma might benefit from combined nivolumab and ipilimumab therapy in second-line treatment. FUNDING: Bristol Myers Squibb.

@article{Ebert2022-rj, abstract = {BACKGROUND: The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 antibodies showed improved progression-free survival and overall survival. We assessed the safety and efficacy of combined nivolumab and ipilimumab therapy in this population. METHODS: This multicentre, open-label, phase 2 trial done in 32 sites in Germany included patients aged 65 years and older with oesophageal squamous cell carcinoma and disease progression or recurrence following first-line therapy. Patients were treated with nivolumab (240 mg fixed dose once every 2 weeks, intravenously) in the safety run-in phase and continued with nivolumab and ipilimumab (nivolumab 240 mg fixed dose once every 2 weeks and ipilimumab 1 mg/kg once every 6 weeks, intravenously). The primary endpoint was overall survival, which was compared with a historical cohort receiving standard chemotherapy in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03416244. FINDINGS: Between March 2, 2018, and Aug 20, 2020, we screened 75 patients with advanced oesophageal squamous cell carcinoma. We enrolled 66 patients (50 [76\%] men and 16 [24\%] women; median age 70·5 years [IQR 67·0-76·0]), 44 (67\%) of whom received combined nivolumab and ipilimumab therapy and 22 (33\%) received nivolumab alone. Median overall survival time at the prespecified data cutoff was 7·2 months (95\% CI 5·7-12·4) and significantly higher than in a historical cohort receiving standard chemotherapy (p=0·0063). The most common treatment-related adverse events were fatigue (12 [29\%] of 42), nausea (11 [26\%]), and diarrhoea (ten [24\%]). Grade 3-5 treatment-related adverse events occurred in 13 (20\%) of 66 patients. Treatment-related death occurred in one patient with bronchiolitis obliterans while on nivolumab and ipilimumab treatment. INTERPRETATION: Patients aged at least 65 years, with advanced oesophageal squamous cell carcinoma might benefit from combined nivolumab and ipilimumab therapy in second-line treatment. FUNDING: Bristol Myers Squibb.}, added-at = {2024-09-10T11:56:37.000+0200}, author = {Ebert, Matthias P and Meindl-Beinker, Nadja M and Gutting, Tobias and Maenz, Martin and Betge, Johannes and Schulte, Nadine and Zhan, Tianzuo and Weidner, Philip and Burgermeister, Elke and Hofheinz, Ralf and Vogel, Arndt and Angermeier, Stefan and Bolling, Claus and de Wit, Maike and Jakobs, Ralf and Karthaus, Meinolf and Stocker, Gertraud and Thuss-Patience, Peter and Leidig, Tobias and Gaiser, Timo and Kather, Jakob N and Haertel, Nicolai}, biburl = {https://puma.scadsai.uni-leipzig.de/bibtex/28574819912cd0dc20724ab59f10ba73d/scadsfct}, copyright = {http://creativecommons.org/licenses/by/4.0/}, interhash = {77081c885fd6a447152e35616a26a6bf}, intrahash = {8574819912cd0dc20724ab59f10ba73d}, journal = {Lancet Healthy Longev.}, keywords = {}, language = {en}, month = jun, number = 6, pages = {e417--e427}, publisher = {Elsevier BV}, timestamp = {2024-09-10T15:15:57.000+0200}, title = {Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer ({RAMONA)}: a multicentre, open-label phase 2 trial}, volume = 3, year = 2022 }